PL2056855T3 - Pochodne alfa-MSH do leczenia fotodermatoz - Google Patents

Pochodne alfa-MSH do leczenia fotodermatoz

Info

Publication number
PL2056855T3
PL2056855T3 PL07800234T PL07800234T PL2056855T3 PL 2056855 T3 PL2056855 T3 PL 2056855T3 PL 07800234 T PL07800234 T PL 07800234T PL 07800234 T PL07800234 T PL 07800234T PL 2056855 T3 PL2056855 T3 PL 2056855T3
Authority
PL
Poland
Prior art keywords
photodermatoses
alpha
treatment
msh derivatives
msh
Prior art date
Application number
PL07800234T
Other languages
English (en)
Inventor
Philippe Wolgen
Original Assignee
Clinuvel Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904745A external-priority patent/AU2006904745A0/en
Application filed by Clinuvel Pharmaceuticals Ltd filed Critical Clinuvel Pharmaceuticals Ltd
Publication of PL2056855T3 publication Critical patent/PL2056855T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07800234T 2006-08-31 2007-08-31 Pochodne alfa-MSH do leczenia fotodermatoz PL2056855T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2006904745A AU2006904745A0 (en) 2006-08-31 Method for Treatment of Photodermatoses
AU2007900862A AU2007900862A0 (en) 2007-02-21 Method for treatment of photodermatoses
PCT/AU2007/001276 WO2008025094A1 (en) 2006-08-31 2007-08-31 Method of treatment of photodermatoses
EP07800234.2A EP2056855B1 (en) 2006-08-31 2007-08-31 Alpha-msh derivatives for the treatment of photodermatoses

Publications (1)

Publication Number Publication Date
PL2056855T3 true PL2056855T3 (pl) 2015-04-30

Family

ID=39135428

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14173509T PL2865422T3 (pl) 2006-08-31 2007-08-31 Pochodne alfa-MSH do leczenia fotodermatoz
PL07800234T PL2056855T3 (pl) 2006-08-31 2007-08-31 Pochodne alfa-MSH do leczenia fotodermatoz

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL14173509T PL2865422T3 (pl) 2006-08-31 2007-08-31 Pochodne alfa-MSH do leczenia fotodermatoz

Country Status (16)

Country Link
US (1) US8334265B2 (pl)
EP (2) EP2056855B1 (pl)
AU (1) AU2007291886B2 (pl)
CA (1) CA2662163C (pl)
CY (1) CY1115804T1 (pl)
DK (2) DK2865422T3 (pl)
ES (2) ES2646049T3 (pl)
HU (2) HUE035074T2 (pl)
LU (1) LUC00062I2 (pl)
NL (1) NL300926I2 (pl)
NZ (1) NZ575133A (pl)
PL (2) PL2865422T3 (pl)
PT (2) PT2865422T (pl)
SI (2) SI2865422T1 (pl)
WO (1) WO2008025094A1 (pl)
ZA (1) ZA200901364B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007291943B2 (en) * 2006-08-28 2013-11-14 Clinuvel Pharmaceuticals Limited Method for reducing incidence or rate of development of skin cancers and related conditions
EP2259794A1 (en) * 2008-02-22 2010-12-15 Clinuvel Pharmaceuticals Limited Method for treatment of photosensitivity and phototoxicity
US20110130705A1 (en) * 2008-03-27 2011-06-02 Clinuvel Pharmaceuticals Limited Therapy for vitiligo
WO2010144344A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
US8979797B2 (en) * 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
EP2487185A1 (en) * 2011-02-11 2012-08-15 Clinuvel Pharmaceuticals Limited Hexapeptide with improved activity in the repair of cellular DNA of dermal cells
US9371555B2 (en) 2012-06-01 2016-06-21 Concordia Laboratories Inc. Lighting systems and methods of using lighting systems for in vitro potency assay for photofrin
WO2014198890A1 (en) * 2013-06-13 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria
WO2015063102A1 (en) * 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh analogues for use in bullous disease
WO2015063099A1 (en) * 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh analogues for use in the treatment of hailey-hailey disease
EP3088417A1 (en) 2015-04-28 2016-11-02 Vallaurix Pte. Ltd. Pharmaceutical compound
EP3088418A1 (en) 2015-04-28 2016-11-02 Vallaurix Pte. Ltd. Pharmaceutical compound
EP3573645B1 (en) * 2017-02-01 2024-03-13 Vallaurix Mc S.A.R.L. Alpha-msh analogues used in the treatment of xeroderma pigmentosum
IL298951A (en) 2020-06-10 2023-02-01 Mitsubishi Tanabe Pharma Corp Prophylactic or therapeutic agent for photodermatosis
WO2021251450A1 (ja) 2020-06-10 2021-12-16 田辺三菱製薬株式会社 ポルフィリン症の予防又は治療剤
US20230248713A1 (en) 2020-06-10 2023-08-10 Mitsubishi Tanabe Pharma Corporation Prophylactic or therapeutic agent for porphyria

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457864A (en) 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
ATE84420T1 (de) * 1986-02-03 1993-01-15 University Patents Inc Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5049547A (en) 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
AU4004699A (en) 1998-05-15 1999-12-06 Quark Biotech, Inc. Mechanical stress induced genes, expression products therefrom, and uses thereof
WO2003072072A1 (en) * 2002-02-26 2003-09-04 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method of stimulation of melanin production and induction of skin tanning
US9345911B2 (en) * 2004-08-04 2016-05-24 Clinuvel Pharmaceuticals Limited Methods of inducing melanogenesis in a subject
JP5449673B2 (ja) * 2004-10-08 2014-03-19 クリヌベール、ファーマスーティカルズ、リミテッド 対象者におけるメラニン形成を誘導するための組成物および方法
AU2007291943B2 (en) * 2006-08-28 2013-11-14 Clinuvel Pharmaceuticals Limited Method for reducing incidence or rate of development of skin cancers and related conditions

Also Published As

Publication number Publication date
CA2662163A1 (en) 2008-03-06
PL2865422T3 (pl) 2018-01-31
AU2007291886B2 (en) 2013-01-10
PT2056855E (pt) 2014-12-12
LUC00062I1 (pl) 2018-02-08
WO2008025094A1 (en) 2008-03-06
DK2865422T3 (da) 2017-11-20
EP2865422B1 (en) 2017-10-18
AU2007291886A1 (en) 2008-03-06
ES2525476T3 (es) 2014-12-23
ZA200901364B (en) 2010-06-30
SI2056855T1 (sl) 2015-01-30
SI2865422T1 (sl) 2017-12-29
US8334265B2 (en) 2012-12-18
EP2865422A1 (en) 2015-04-29
EP2056855B1 (en) 2014-09-17
ES2646049T3 (es) 2017-12-11
DK2056855T3 (en) 2014-12-15
LUC00062I2 (pl) 2018-03-28
EP2056855A4 (en) 2013-06-19
HUS1800006I1 (hu) 2018-05-02
CA2662163C (en) 2015-11-24
US20100120668A1 (en) 2010-05-13
EP2056855A1 (en) 2009-05-13
HUE035074T2 (en) 2018-05-02
HK1130208A1 (en) 2009-12-24
CY1115804T1 (el) 2017-01-25
NZ575133A (en) 2011-11-25
NL300926I2 (nl) 2018-03-20
PT2865422T (pt) 2017-11-14

Similar Documents

Publication Publication Date Title
HUS1800006I1 (hu) Alfa-MSH származékok fotodermatózisok kezelésére
ZA200805877B (en) Pyridiazinone derivatives for tumour treatment
IL198847A (en) Process for making 2-imino-thiazolidine-4-on and several such histories
IL197137A0 (en) Tonsillitis treatment
IL192690A0 (en) Hydantoin derivatives for the treatment of inflammatory disorders
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
ZA200805159B (en) Imidazole derivatives for the treatment of gastrointestinal disorders
ZA201007362B (en) Conjugates for the treatment of mesothelioma
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
ZA200904328B (en) Prophylactic or therapeutic agent for alopecia
IL226363A0 (en) Compounds and methods for treating cancer
PL380561A1 (pl) Sposób otrzymywania pochodnych antracyklin
ZA200800921B (en) Pyrazolone derivatives for the treatment of tuberculosis
IL194737A0 (en) 2-alkenyl-3-aminothiophene derivatives and processes for the preparation thereof
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0602857D0 (en) The treatment of sialorrhoea
ZA200806180B (en) Benzoisoindole derivatives for the treatment of pain
GB0604114D0 (en) Combinations for the treatment of cancer
GB0602858D0 (en) The treatment of sialorrhoea
GB0602855D0 (en) The Treatment Of Sialorrhoea
ZA200707384B (en) Process for the preparation of 1-aminopiperidine derivatives
IL194261A0 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
HK1122032A (en) Benzoisoindole derivatives for the treatment of pain
GB0715257D0 (en) Phenylthiazolylpiperazine derivatives for the treatment of nuero degenerative diseases